Skip Nav Destination
Issues
1 January 2008
-
Cover Image
Cover Image
Inheritance of a germ line mutation in the BRCA1 or BRCA2 (BRCA1/2) gene confers early onset breast and ovarian cancer risk that is many times higher than that in the general population. Gao and colleagues report that a polymorphism in tumor suppressor gene RASSF1A (A133S) also confers an increased risk of developing breast cancer in Caucasian women. Importantly, they found that the average age at breast cancer diagnosis for BRCA1/2 mutation carriers with A133S is six years earlier than in individuals with wild-type RASSF1A. They hypothesized that RASSF1A modifies the risk of breast cancer in BRCA1/2 mutation carriers.Close Modal
This finding provides more evidence of the importance of the RASSF1A tumor suppressor gene as the A133S variant has been shown to have lost functional activity compared to wild-type RASSF1A. It also suggests the need for a large-scale study to validate the effect of A133S in the development of breast and other types of cancer. If confirmed, RASSF1A A133S could be developed as a molecular biomarker for refining cancer risk estimates for women at higher risk for breast cancer. Women with a BRCA1/2 mutation and wild-type RASSF1A (A133S) might use such information to aid decisions regarding timing of risk-reducing interventions, such as prophylactic surgery or chemoprevention. For details, see the article by Gao and colleagues on page 22 of this issue. - PDF Icon PDF LinkTable of Contents
ISSN 0008-5472
EISSN 1538-7445
Journal Archive
Cancer Research (1941-Present; volumes 1-current)
(ISSN 0008-5472) Published twice monthly since 1987. From 1941-1986, published monthly.The American Journal of Cancer (1931-1940; volumes 15-40)
(ISSN 0099-7374) Published quarterly in 1931, bimonthly in 1932, and monthly from 1933 to 1940. The journal changed title to Cancer Research in 1941.The Journal of Cancer Research (1916-1930); volumes 1-14)
(ISSN 0099-7013) Published quarterly from 1916 through 1930 (publication was suspended from November 1922 to March 1924). The journal changed title to The American Journal of Cancer in 1931.Table of Contents
Editorial
Reviews
Perspectives in Cancer Research
Priority Reports
RASSF1A Polymorphism A133S Is Associated with Early Onset Breast Cancer in BRCA1/2 Mutation Carriers
Boning Gao; Xian-Jin Xie; Chunxian Huang; David S. Shames; Tina T-L. Chen; Cheryl M. Lewis; Aihua Bian; Bifeng Zhang; Olufunmilayo I. Olopade; Judy E. Garber; David M. Euhus; Gail E. Tomlinson; John D. Minna
Molecular Biology, Pathobiology, and Genetics
Cell, Tumor, and Stem Cell Biology
Paxillin Is a Target for Somatic Mutations in Lung Cancer: Implications for Cell Growth and Invasion
Ramasamy Jagadeeswaran; Hanna Surawska; Soundararajan Krishnaswamy; Varalakshmi Janamanchi; A. Craig Mackinnon; Tanguy Y. Seiwert; Sivakumar Loganathan; Rajani Kanteti; Trevor Reichman; Vidya Nallasura; Stuart Schwartz; Leonardo Faoro; Yi-Ching Wang; Luc Girard; Maria S. Tretiakova; Salman Ahmed; Osvaldo Zumba; Lioubov Soulii; Vytas P. Bindokas; Livia L. Szeto; Gavin J. Gordon; Raphael Bueno; David Sugarbaker; Mark W. Lingen; Martin Sattler; Thomas Krausz; Wickii Vigneswaran; Viswanathan Natarajan; John Minna; Everett E. Vokes; Mark K. Ferguson; Aliya N. Husain; Ravi Salgia
Therapeutic Window of MuS110, a Single-Chain Antibody Construct Bispecific for Murine EpCAM and Murine CD3
Maria Amann; Klaus Brischwein; Petra Lutterbuese; Larissa Parr; Laetitia Petersen; Grit Lorenczewski; Eva Krinner; Sandra Bruckmeier; Sandra Lippold; Roman Kischel; Ralf Lutterbuese; Peter Kufer; Patrick A. Baeuerle; Bernd Schlereth
Experimental Therapeutics, Molecular Targets, and Chemical Biology
A Vascular Targeted Pan Phosphoinositide 3-Kinase Inhibitor Prodrug, SF1126, with Antitumor and Antiangiogenic Activity
Joseph R. Garlich; Pradip De; Nandini Dey; Jing Dong Su; Xiaodong Peng; Antoinette Miller; Ravoori Murali; Yiling Lu; Gordon B. Mills; Vikas Kundra; H-K. Shu; Qiong Peng; Donald L. Durden
Capsiate, a Nonpungent Capsaicin-Like Compound, Inhibits Angiogenesis and Vascular Permeability via a Direct Inhibition of Src Kinase Activity
Bo-Jeong Pyun; Sun Choi; Yoonji Lee; Tae-Woong Kim; Jeong-Ki Min; Yonghak Kim; Byung-Dong Kim; Jeong-Han Kim; Tae-Yoon Kim; Young-Myeong Kim; Young-Guen Kwon
Transcription Factor Stat5 Synergizes with Androgen Receptor in Prostate Cancer Cells
Shyh-Han Tan; Ayush Dagvadorj; Feng Shen; Lei Gu; Zhiyong Liao; Junaid Abdulghani; Ying Zhang; Edward P. Gelmann; Tobias Zellweger; Zoran Culig; Tapio Visakorpi; Lukas Bubendorf; Robert A. Kirken; James Karras; Marja T. Nevalainen
Homologous Recombination Is the Principal Pathway for the Repair of DNA Damage Induced by Tirapazamine in Mammalian Cells
James W. Evans; Sophia B. Chernikova; Lisa A. Kachnic; Judit P. Banath; Olivier Sordet; Yvette M. Delahoussaye; Alejandro Treszezamsky; Brian H. Chon; Zhihui Feng; Yongchuan Gu; William R. Wilson; Yves Pommier; Peggy L. Olive; Simon N. Powell; J. Martin Brown
Immunology
Endocrinology
Clinical Research
Epidemiology
Insulin, Insulin-like Growth Factor-I, Endogenous Estradiol, and Risk of Colorectal Cancer in Postmenopausal Women
Marc J. Gunter; Donald R. Hoover; Herbert Yu; Sylvia Wassertheil-Smoller; Thomas E. Rohan; JoAnn E. Manson; Barbara V. Howard; Judith Wylie-Rosett; Garnet L. Anderson; Gloria Y.F. Ho; Robert C. Kaplan; Jixin Li; Xiaonan Xue; Tiffany G. Harris; Robert D. Burk; Howard D. Strickler
Correction
Advertisement